Trials / Completed
CompletedNCT05371028
A Study of Teduglutide (Revestive®) in Participants With Short Bowel Syndrome (SBS) in Canada
A Non-interventional, Multicentre Retrospective Study of the Effectiveness and Safety of Teduglutide (REVESTIVE®) in Short Bowel Syndrome Patients in Canada
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 52 (actual)
- Sponsor
- Takeda · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main aim of this study is to assess the effectiveness and side effects of teduglutide (Revestive®) in real-world clinical practice setting in adult participants with intestinal failure due to short bowel syndrome (SBS-IF) in Canada. This study is about collecting existing data only; participants receive teduglutide (Revestive®) by their doctors according to the clinical practice but not as part of this study. No new information will be collected during this study. The study will be conducted using data from the Takeda OnePath Patient Support Program (PSP) or Takeda Global Pharmacovigilance.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Non-interventional Study | This is non-interventional study. |
Timeline
- Start date
- 2023-09-23
- Primary completion
- 2025-02-19
- Completion
- 2025-02-19
- First posted
- 2022-05-12
- Last updated
- 2025-04-06
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT05371028. Inclusion in this directory is not an endorsement.